Related Experiment Video
Updated: Sep 28, 2026

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
Published on: May 23, 2025
Pharmacokinetic and pharmacodynamic evaluation of cyclosporin A O/W-emulsion in rats
Soo-Jin Kim1, Hoo-Kyun Choi, Yong-Bok Lee
1College of Pharmacy and Research Institute of Drug Development, Chonnam National University, 300 Yongbong-Dong, Buk-Gu, Kwangju 500-757, South Korea.
Abstract:
The pharmacokinetics and pharmacodynamics of the cyclosporin A (CSA) O/W-emulsion were studied after intravenous and oral administration to Sprague-Dawley rats. Two commercial products, CIPOL Inj. and Sandimmun Neoral, were used as the reference formulations. CSA concentration and lymphocyte populations in whole blood were measured by TDxFLx and Coulter STKS, respectively. The pharmacokinetic and pharmacodynamic parameters were obtained by fitting experimental data to two-compartment model and to indirect pharmacodynamic model, respectively, using WINNONLIN. The area under the concentration-time curve (AUC), terminal half-lives (T(1/2)), total clearance (CL(t)) and relative bioavailability (F) after intravenous administration of CSA O/W-emulsion were not significantly different from those of intravenous administration of CIPOL Inj. (P>0.05). In oral administration, AUC and C(max) of CSA O/W-emulsion were significantly decreased (P<0.05), while T(1/2), MRT, T(max) and F were not significantly different (P>0.05) from those of Sandimmun Neoral. However, the area between the baseline and effect curves (ABEC) and pharmacodynamic efficiency (EFF) of CSA O/W-emulsion were significantly greater than those of references regardless of routes of administration (P<0.05). The pharmacodynamic availability (F(PD)) of CSA O/W-emulsion was 1.79- and 2.13-fold higher than that of CIPOL Inj.and Sandimmun Neroal (P<0.05), respectively.
Related Concept Videos
Measurement of Bioavailability: Pharmacokinetic Methods
Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
Pharmacokinetic–Pharmacodynamic Relationship: Problems
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Measurement of Bioavailability: Pharmacodynamic Methods
Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect
